Journal of Comprehensive Pediatrics

Published by: Kowsar

Pharmacogenetics, the Promise of Translating Personalized Medicine into Clinical Pediatrics

Mahsa Motavaf 1 and Mansour Bahrami 2 , *
Authors Information
1 Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, IR Iran
2 Department of Pediatrics, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
Article information
  • Journal of Comprehensive Pediatrics: May 01, 2016, 7 (2); e38168
  • Published Online: May 14, 2016
  • Article Type: Editorial
  • Received: April 3, 2016
  • Accepted: April 3, 2016
  • DOI: 10.17795/compreped-38168

To Cite: Motavaf M, Bahrami M. Pharmacogenetics, the Promise of Translating Personalized Medicine into Clinical Pediatrics, J Compr Ped. 2016 ; 7(2):e38168. doi: 10.17795/compreped-38168.

Copyright © 2016, Iranian Society of Pediatrics. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
Footnote
References
  • 1. Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, et al. A global reference for human genetic variation. Nature. 2015; 526(7571): 68-74[DOI][PubMed]
  • 2. Hoppe R, Brauch H, Kroetz DL, Esteller M. Exploiting the complexity of the genome and transcriptome using pharmacogenomics towards personalized medicine. Genome Biol. 2011; 12(1): 301[DOI][PubMed]
  • 3. He Y, Hoskins JM, McLeod HL. Copy number variants in pharmacogenetic genes. Trends Mol Med. 2011; 17(5): 244-51[DOI][PubMed]
  • 4. Nguyen CM, Mendes MA, Ma JD. Thiopurine methyltransferase (TPMT) genotyping to predict myelosuppression risk. PLoS Curr. 2011; 3
  • 5. Zhou S. Clinical pharmacogenomics of thiopurine S-methyltransferase. Curr Clin Pharmacol. 2006; 1(1): 119-28[PubMed]
  • 6. Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet. 1990; 336(8709): 225-9
  • 7. Cheok MH, Evans WE. Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nat Rev Cancer. 2006; 6(2): 117-29[DOI][PubMed]
  • 8. De Mattia E, Toffoli G. C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation. Eur J Cancer. 2009; 45(8): 1333-51[DOI][PubMed]
  • 9. Ulrich CM, Yasui Y, Storb R, Schubert MM, Wagner JL, Bigler J, et al. Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood. 2001; 98(1): 231-4[PubMed]
  • 10. Spyridopoulou KP, Dimou NL, Hamodrakas SJ, Bagos PG. Methylene tetrahydrofolate reductase gene polymorphisms and their association with methotrexate toxicity: a meta-analysis. Pharmacogenet Genomics. 2012; 22(2): 117-33[DOI][PubMed]
  • 11. Shaw K, Amstutz U, Carleton BC. Using pharmacogenetics to understand adverse drug reactions in children. Paediatr Child Health. 2011; 16(9): 537-8[PubMed]
  • 12. Ross CJ, Katzov-Eckert H, Dube MP, Brooks B, Rassekh SR, Barhdadi A, et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet. 2009; 41(12): 1345-9[DOI][PubMed]
  • 13. Brock PR, Knight KR, Freyer DR, Campbell KC, Steyger PS, Blakley BW, et al. Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. J Clin Oncol. 2012; 30(19): 2408-17[DOI][PubMed]
  • 14. McGhee SA. How the practice of allergy shows the promise and challenge of personalized medicine. Mol Genet Metab. 2011; 104(1-2): 3-6[DOI][PubMed]
  • 15. Szefler SJ, Martin RJ, King TS, Boushey HA, Cherniack RM, Chinchilli VM, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol. 2002; 109(3): 410-8[PubMed]
  • 16. Szefler SJ, Phillips BR, Martinez FD, Chinchilli VM, Lemanske RF, Strunk RC, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol. 2005; 115(2): 233-42[DOI][PubMed]
  • 17. Martinez FD, Graves PE, Baldini M, Solomon S, Erickson R. Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest. 1997; 100(12): 3184-8[DOI][PubMed]
  • 18. Israel E, Drazen JM, Liggett SB, Boushey HA, Cherniack RM, Chinchilli VM, et al. The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med. 2000; 162(1): 75-80[DOI][PubMed]
  • 19. Carroll CL, Stoltz P, Schramm CM, Zucker AR. Beta2-adrenergic receptor polymorphisms affect response to treatment in children with severe asthma exacerbations. Chest. 2009; 135(5): 1186-92[DOI][PubMed]
  • 20. Wechsler ME, Lehman E, Lazarus SC, Lemanske RJ, Boushey HA, Deykin A, et al. beta-Adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med. 2006; 173(5): 519-26[DOI][PubMed]
  • 21. Taylor DR, Drazen JM, Herbison GP, Yandava CN, Hancox RJ, Town GI. Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism. Thorax. 2000; 55(9): 762-7[PubMed]
  • 22. Brothers KB. Ethical issues in pediatric pharmacogenomics. J Pediatr Pharmacol Ther. 2013; 18(3): 192-8[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments